Headquartered in New Haven, CT·Fiscal year ends December·NASDAQ: IVVD·invivyd.com
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a commercial-stage biopharmaceutical company developing monoclonal antibodies (mAbs) for protection against serious viral infectious diseases, starting with SARS-CoV-2. It uses a proprietary integrated technology platform to assess, monitor, develop and adapt antibodies as viruses evolve.
**Commercial product:** PEMGARDA (pemivibart) is a half-life extended mAb authorized by the U.S. FDA under an Emergency Use Authorization since March 2024. It is used for pre-exposure prophylaxis of COVID-19 in moderately-to-severely immunocompromised adults and adolescents and is sold through an in-house sales force. HHS has announced that the underlying emergency declaration terminates June 29, 2027.
**Lead candidate:** VYD2311 (ibramvibart) is an intramuscular-capable mAb built on the same antibody backbone as pemivibart. It is being studied in the REVOLUTION program:
- DECLARATION, a Phase 3 prevention trial of about 2,400 participants intended to support a BLA under the FDA Accelerated Approval Program;
- LIBERTY, a Phase 3 safety and co-administration study versus an mRNA vaccine;
- FLINTLOCK, a Phase 2 trial in Long COVID and COVID vaccine injury, conducted with the SPEAR Study Group.
**Measles:** VMS063 is a preclinical measles Fusion-protein mAb candidate for treatment and prevention, targeted for clinical development in 2027. Updated
Pre-Market Stock Futures: Futures are trading higher as we get ready to start a holiday-shortened trading week after an outstanding triple-witching Friday rally that may have kicked the “Santa Claus” rally into…
Invivyd, Inc. (Nasdaq: IVVD) is a commercial-stage biopharmaceutical company developing monoclonal antibodies (mAbs) for protection against serious viral infectious diseases, starting with SARS-CoV-2.
What is the IVVD stock price target?
The Wall Street consensus 12-month price target for IVVD is $10.00.